Does the media prefer IRD or GANX?

In the previous week, Gain Therapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 7 mentions for Gain Therapeutics and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.57 beat Gain Therapeutics' score of 0.45 indicating that Opus Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AMRN or GANX?

Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 292.67%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Amarin. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is AMRN or GANX more profitable?

Gain Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Amarin -15.51% -2.99% -2.07% Gain Therapeutics N/A -201.44% -136.24%

Does the media prefer AMRN or GANX?

In the previous week, Gain Therapeutics had 3 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Gain Therapeutics and 4 mentions for Amarin. Gain Therapeutics' average media sentiment score of 0.45 beat Amarin's score of 0.40 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GANX or LRMR more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Larimar Therapeutics N/A -134.14% -96.00%

Does the media refer more to GANX or LRMR?

In the previous week, Larimar Therapeutics had 9 more articles in the media than Gain Therapeutics. MarketBeat recorded 16 mentions for Larimar Therapeutics and 7 mentions for Gain Therapeutics. Larimar Therapeutics' average media sentiment score of 0.79 beat Gain Therapeutics' score of 0.45 indicating that Larimar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or GANX more profitable?

Zentalis Pharmaceuticals' return on equity of -53.61% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -53.61% -40.67% Gain Therapeutics N/A -201.44% -136.24%

Does the media prefer ZNTL or GANX?

In the previous week, Gain Therapeutics had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Gain Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Gain Therapeutics' average media sentiment score of 0.45 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GANX or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Galectin Therapeutics N/A N/A -164.69%

Does the media favor GANX or GALT?

In the previous week, Gain Therapeutics had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for Gain Therapeutics and 5 mentions for Galectin Therapeutics. Gain Therapeutics' average media sentiment score of 0.45 beat Galectin Therapeutics' score of -0.83 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Gain Therapeutics (GANX) Competitors

$1.91 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.90 -0.01 (-0.63%)

As of 07/2/2026 07:57 PM Eastern

Compare

GANX vs. IRD, AMRN, LRMR, ZNTL, and GALT

Should you buy Gain Therapeutics stock or one of its competitors? MarketBeat compares Gain Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gain Therapeutics include Opus Genetics (IRD), Amarin (AMRN), Larimar Therapeutics (LRMR), Zentalis Pharmaceuticals (ZNTL), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry.

How does Gain Therapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gain Therapeutics has lower revenue, but higher earnings than Opus Genetics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$11.98M	29.15	-$49.59M	-$1.33	N/A
Gain Therapeutics	$50K	1,629.23	-$20.16M	-$0.58	N/A

Opus Genetics presently has a consensus target price of $10.77, suggesting a potential upside of 154.59%. Gain Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 292.67%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 5 more articles in the media than Opus Genetics. MarketBeat recorded 7 mentions for Gain Therapeutics and 2 mentions for Opus Genetics. Opus Genetics' average media sentiment score of 0.57 beat Gain Therapeutics' score of 0.45 indicating that Opus Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Opus Genetics has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Gain Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -892.36%. Gain Therapeutics' return on equity of -201.44% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Gain Therapeutics	N/A	-201.44%	-136.24%

Summary

Opus Genetics beats Gain Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Gain Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 292.67%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 3 more articles in the media than Amarin. MarketBeat recorded 7 mentions for Gain Therapeutics and 4 mentions for Amarin. Gain Therapeutics' average media sentiment score of 0.45 beat Amarin's score of 0.40 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.3% of Amarin shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Gain Therapeutics has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.61	-$38.80M	-$0.65	N/A
Gain Therapeutics	$50K	1,629.23	-$20.16M	-$0.58	N/A

Gain Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Gain Therapeutics	N/A	-201.44%	-136.24%

Amarin has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

Summary

Gain Therapeutics beats Amarin on 10 of the 17 factors compared between the two stocks.

How does Gain Therapeutics compare to Larimar Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Larimar Therapeutics' return on equity of -134.14% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Gain Therapeutics has higher revenue and earnings than Larimar Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,629.23	-$20.16M	-$0.58	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

In the previous week, Larimar Therapeutics had 9 more articles in the media than Gain Therapeutics. MarketBeat recorded 16 mentions for Larimar Therapeutics and 7 mentions for Gain Therapeutics. Larimar Therapeutics' average media sentiment score of 0.79 beat Gain Therapeutics' score of 0.45 indicating that Larimar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Gain Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 292.67%. Larimar Therapeutics has a consensus price target of $12.71, indicating a potential upside of 290.01%. Given Gain Therapeutics' higher probable upside, research analysts clearly believe Gain Therapeutics is more favorable than Larimar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Summary

Larimar Therapeutics beats Gain Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Zentalis Pharmaceuticals' return on equity of -53.61% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%
Gain Therapeutics	N/A	-201.44%	-136.24%

Gain Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Gain Therapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	4.71	-$137.06M	-$1.73	N/A
Gain Therapeutics	$50K	1,629.23	-$20.16M	-$0.58	N/A

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the broader market.

Zentalis Pharmaceuticals presently has a consensus price target of $5.83, suggesting a potential upside of 30.79%. Gain Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 292.67%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Gain Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

12.0% of Gain Therapeutics shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Gain Therapeutics had 6 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 7 mentions for Gain Therapeutics and 1 mentions for Zentalis Pharmaceuticals. Gain Therapeutics' average media sentiment score of 0.45 beat Zentalis Pharmaceuticals' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gain Therapeutics beats Zentalis Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Gain Therapeutics compare to Galectin Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Gain Therapeutics presently has a consensus target price of $7.50, indicating a potential upside of 292.67%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 143.90%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Gain Therapeutics is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Gain Therapeutics has higher revenue and earnings than Galectin Therapeutics. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,629.23	-$20.16M	-$0.58	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

In the previous week, Gain Therapeutics had 2 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for Gain Therapeutics and 5 mentions for Galectin Therapeutics. Gain Therapeutics' average media sentiment score of 0.45 beat Galectin Therapeutics' score of -0.83 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galectin Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Gain Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Galectin Therapeutics' return on equity of 0.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Galectin Therapeutics	N/A	N/A	-164.69%

Summary

Gain Therapeutics beats Galectin Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$81.47M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-3.29	20.06	28.02	24.70
Price / Sales	1,629.23	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	3.98	4.32	10.96	6.46
Net Income	-$20.16M	$64.45M	$3.57B	$337.01M
7 Day Performance	9.14%	2.97%	2.12%	1.69%
1 Month Performance	12.35%	6.83%	5.25%	3.81%
1 Year Performance	13.02%	29.07%	33.29%	23.90%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	2.5189 of 5 stars	$1.91 flat	$7.50 +292.7%	+13.0%	$81.47M	$50K	N/A	20	Analyst Forecast Gap Up
IRD Opus Genetics	3.0155 of 5 stars	$4.11 +1.2%	$10.77 +162.0%	+323.0%	$335.22M	$14.20M	N/A	14	News Coverage
AMRN Amarin	1.5589 of 5 stars	$15.94 +0.1%	N/A	+1.1%	$333.83M	$213.65M	N/A	360
LRMR Larimar Therapeutics	3.1878 of 5 stars	$3.05 -4.7%	$13.17 +331.7%	+3.8%	$332.42M	N/A	N/A	30	News Coverage Analyst Forecast Analyst Revision
ZNTL Zentalis Pharmaceuticals	2.0493 of 5 stars	$4.85 +5.2%	$5.83 +20.3%	+256.8%	$328.17M	$67.43M	N/A	160

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. IRD, AMRN, LRMR, ZNTL, and GALT

How does Gain Therapeutics compare to Opus Genetics?

Summary

How does Gain Therapeutics compare to Amarin?

Summary

How does Gain Therapeutics compare to Larimar Therapeutics?

Summary

How does Gain Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Gain Therapeutics compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. IRD, AMRN, LRMR, ZNTL, and GALT

How does Gain Therapeutics compare to Opus Genetics?

Do insiders & institutionals hold more shares of IRD or GANX?

Which has stronger valuation and earnings, IRD or GANX?

Do analysts recommend IRD or GANX?

Does the media prefer IRD or GANX?

Which has more volatility & risk, IRD or GANX?

Is IRD or GANX more profitable?

Summary

How does Gain Therapeutics compare to Amarin?

Do analysts prefer AMRN or GANX?

Does the media prefer AMRN or GANX?

Do insiders & institutionals hold more shares of AMRN or GANX?

Which has stronger earnings & valuation, AMRN or GANX?

Is AMRN or GANX more profitable?

Which has more risk & volatility, AMRN or GANX?

Summary

How does Gain Therapeutics compare to Larimar Therapeutics?

Is GANX or LRMR more profitable?

Which has preferable earnings and valuation, GANX or LRMR?

Which has more risk and volatility, GANX or LRMR?

Does the media refer more to GANX or LRMR?

Do insiders & institutionals have more ownership in GANX or LRMR?

Do analysts recommend GANX or LRMR?

Summary

How does Gain Therapeutics compare to Zentalis Pharmaceuticals?

Is ZNTL or GANX more profitable?

Which has higher valuation and earnings, ZNTL or GANX?

Which has more risk and volatility, ZNTL or GANX?

Do analysts rate ZNTL or GANX?

Do institutionals & insiders have more ownership in ZNTL or GANX?

Does the media prefer ZNTL or GANX?

Summary

How does Gain Therapeutics compare to Galectin Therapeutics?

Do analysts prefer GANX or GALT?

Which has better valuation & earnings, GANX or GALT?

Does the media favor GANX or GALT?

Do institutionals and insiders believe in GANX or GALT?

Which has more risk and volatility, GANX or GALT?

Is GANX or GALT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools